Lana Pine

The mean percentage change from baseline in lumbar spine bone mineral density was comparable between treatment groups at 18 months.

Patients with RA had an increased risk of fractures compared with controls, with significant baseline predictors for future fractures identified as higher age, low body mass index, and low bone mineral density.

Factors independently associated with persistently active RA included age, gender, previous or current smoking status, and social deprivation.

Jacques-Eric Gottenberg, MD, PhD, discusses the encouraging results of a phase 2 study evaluating nipocalimab for the treatment of Sjögren's syndrome.

A significantly larger proportion of patients in the dotinurad group met the primary endpoint compared with the febuxostat group at week 24.

The primary endpoint was met by 51% of patients in the high dose group and 43% of patients in the low dose group, compared with only 8% of those receiving placebo.

Reductions in the mean number of tender joints from baseline to month 6 were greater among patients in the treatment groups compared with placebo.

Casey Schlacher discusses the FDA approval of the new weight-based oral solution, RINVOQ LQ (upadacitinib), for treating pediatric patients with arthritis, highlighting its importance for improving patient outcomes and quality of life.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

The study identified 6 key themes highlighting how gout impacts work life, including the severity of physical symptoms, the challenge of physically demanding jobs, and emotional and social experiences.

If approved, zasocitinib could become a leading oral treatment for PsA.

Older children (aged >5 years) with JIA exhibited a 40% to 45% higher point prevalence of active disease at month 12 when compared with younger patients.

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

The rheumatology month in review for June 2024 addresses the critical role of psychological, socioeconomic, and lifestyle factors in the management of rheumatic diseases, particularly rheumatoid arthritis and fibromyalgia.

The biosimilars month in review underscores the efficacy and safety of biosimilars in rheumatology, including recent studies supporting the growing confidence in these treatments across disease spaces.

Diana Girnita, MD, PhD, highlights the crucial role of patient education, the integration of traditional and integrative medicine, and the importance of reliable information for improving health outcomes in chronic conditions.

Shai Efrati, MD, explains how his research aims to address the root cause of fibromyalgia: damaged brain tissue.

The study demonstrated clinical similarity between the proposed biosimilar and the reference products.

Treatment involved repairing the brain tissue using HBOT, which led to significant symptom improvement.

Robust clinical data showed ustekinumab-ttwe demonstrated similar safety and efficacy compared with the reference product.

Aflibercept-mrbb showed comparable safety, efficacy, pharmacokinetics, and immunogenicity compared with the reference product.

Among all groups, fewer men with rheumatic disease were childless compared with controls.

At 8 months follow-up, 86.0% of patients with rheumatoid arthritis were in remission and 94.2% exhibited low disease activity.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

A post hoc analysis of the MIRROR trial suggests comprehensive gout management should aim for remission, incorporating both uric acid lowering and broader symptom improvements.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.